ESR1 and neoplasm: Our results are analogous to those obtained by Mohammed et al. [16] and Finlay-Schultz et al. [17], who compared progestogen/E2 treatment to E2 alone in ERα-positive/PR-positive breast cancer cells (MCF-7 and T-47D) and patient derived tumor xenografts, respectively.